vs
CHAMPIONS ONCOLOGY, INC.（CSBR）与Rent the Runway, Inc.（RENT）财务数据对比。点击上方公司名可切换其他公司
CHAMPIONS ONCOLOGY, INC.的季度营收约是Rent the Runway, Inc.的1.4倍（$15.0M vs $10.6M），Rent the Runway, Inc.净利率更高（721.7% vs 1.8%，领先719.9%），CHAMPIONS ONCOLOGY, INC.同比增速更快（11.5% vs 10.4%），过去两年CHAMPIONS ONCOLOGY, INC.的营收复合增速更高（11.8% vs 1.0%）
冠军肿瘤学公司是一家成立于2007年的美国科技企业，由约翰霍普金斯大学肿瘤学家David Sidransky博士创立。该公司开发名为TumorGrafts的小鼠模型（又称小鼠化身），可用于测试多种化疗方案、靶向药物与单克隆抗体，帮助为癌症患者筛选潜在的可行治疗方案。
Rent the Runway Inc.是总部位于纽约的美国电商平台，由珍妮弗·海曼与珍妮弗·弗莱斯于2009年11月创立，主打设计师品牌服饰与配饰的租赁、订阅以及购买服务，是设计师服饰共享租赁模式的开创平台之一。
CSBR vs RENT — 直观对比
营收规模更大
CSBR
是对方的1.4倍
$10.6M
营收增速更快
CSBR
高出1.0%
10.4%
净利率更高
RENT
高出719.9%
1.8%
两年增速更快
CSBR
近两年复合增速
1.0%
损益表 — Q2 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $15.0M | $10.6M |
| 净利润 | $268.0K | $76.5M |
| 毛利率 | 51.7% | -126.4% |
| 营业利润率 | 1.2% | -152.8% |
| 净利率 | 1.8% | 721.7% |
| 营收同比 | 11.5% | 10.4% |
| 净利润同比 | -63.2% | 504.8% |
| 每股收益（稀释后） | $0.02 | $13.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSBRRENT
| Q4 25 | $15.0M | $10.6M | ||
| Q3 25 | $14.0M | $11.7M | ||
| Q2 25 | $12.4M | $7.6M | ||
| Q1 25 | $17.0M | $11.8M | ||
| Q4 24 | $13.5M | $9.6M | ||
| Q3 24 | $14.1M | $10.4M | ||
| Q2 24 | $14.0M | $8.9M | ||
| Q1 24 | $12.0M | $10.4M |
净利润CSBRRENT
| Q4 25 | $268.0K | $76.5M | ||
| Q3 25 | $-436.0K | $-26.4M | ||
| Q2 25 | $-1.8M | $-26.1M | ||
| Q1 25 | $4.5M | $-13.4M | ||
| Q4 24 | $728.0K | $-18.9M | ||
| Q3 24 | $1.3M | $-15.6M | ||
| Q2 24 | $-109.0K | $-22.0M | ||
| Q1 24 | $-2.5M | $-24.8M |
毛利率CSBRRENT
| Q4 25 | 51.7% | -126.4% | ||
| Q3 25 | 42.9% | -92.3% | ||
| Q2 25 | 41.1% | -168.4% | ||
| Q1 25 | 61.2% | -71.2% | ||
| Q4 24 | 44.9% | -122.9% | ||
| Q3 24 | 49.7% | -98.1% | ||
| Q2 24 | 48.2% | -131.5% | ||
| Q1 24 | 34.7% | -93.3% |
营业利润率CSBRRENT
| Q4 25 | 1.2% | -152.8% | ||
| Q3 25 | -3.8% | -171.8% | ||
| Q2 25 | -16.2% | -259.2% | ||
| Q1 25 | 26.4% | -65.3% | ||
| Q4 24 | 5.4% | -142.7% | ||
| Q3 24 | 9.5% | -92.3% | ||
| Q2 24 | -1.9% | -185.4% | ||
| Q1 24 | -21.4% | -185.6% |
净利率CSBRRENT
| Q4 25 | 1.8% | 721.7% | ||
| Q3 25 | -3.1% | -225.6% | ||
| Q2 25 | -14.9% | -343.4% | ||
| Q1 25 | 26.4% | -113.6% | ||
| Q4 24 | 5.4% | -196.9% | ||
| Q3 24 | 9.3% | -150.0% | ||
| Q2 24 | -0.8% | -247.2% | ||
| Q1 24 | -21.1% | -238.5% |
每股收益（稀释后）CSBRRENT
| Q4 25 | $0.02 | $13.65 | ||
| Q3 25 | $-0.03 | $-6.55 | ||
| Q2 25 | $-0.12 | $-6.58 | ||
| Q1 25 | $0.31 | $-2.72 | ||
| Q4 24 | $0.05 | $-4.70 | ||
| Q3 24 | $0.09 | $-4.17 | ||
| Q2 24 | $-0.01 | $-6.03 | ||
| Q1 24 | $-0.19 | $-5.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $50.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2M | $-35.1M |
| 总资产 | $30.2M | $231.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSBRRENT
| Q4 25 | $8.5M | $50.7M | ||
| Q3 25 | $10.3M | $43.6M | ||
| Q2 25 | $9.8M | $70.4M | ||
| Q1 25 | $3.2M | $77.4M | ||
| Q4 24 | $2.8M | $74.1M | ||
| Q3 24 | $2.9M | $76.6M | ||
| Q2 24 | $2.6M | $82.0M | ||
| Q1 24 | $4.5M | $84.0M |
总债务CSBRRENT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $340.6M | ||
| Q1 25 | — | $333.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CSBRRENT
| Q4 25 | $4.2M | $-35.1M | ||
| Q3 25 | $3.5M | $-232.1M | ||
| Q2 25 | $3.8M | $-207.1M | ||
| Q1 25 | $5.5M | $-182.5M | ||
| Q4 24 | $681.0K | $-171.2M | ||
| Q3 24 | $-332.0K | $-154.5M | ||
| Q2 24 | $-1.9M | $-141.3M | ||
| Q1 24 | $-2.1M | $-122.3M |
总资产CSBRRENT
| Q4 25 | $30.2M | $231.0M | ||
| Q3 25 | $30.5M | $219.0M | ||
| Q2 25 | $32.3M | $245.3M | ||
| Q1 25 | $30.6M | $240.0M | ||
| Q4 24 | $25.2M | $251.6M | ||
| Q3 24 | $24.9M | $257.4M | ||
| Q2 24 | $26.1M | $278.4M | ||
| Q1 24 | $26.8M | $278.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $-1.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | — |
| 自由现金流率自由现金流/营收 | -13.1% | — |
| 资本支出强度资本支出/营收 | 1.6% | — |
| 现金转化率经营现金流/净利润 | -6.47× | -0.02× |
| 过去12个月自由现金流最近4个季度 | $5.6M | — |
8季度趋势，按日历期对齐
经营现金流CSBRRENT
| Q4 25 | $-1.7M | $-1.4M | ||
| Q3 25 | $600.0K | $-10.5M | ||
| Q2 25 | $6.9M | $8.3M | ||
| Q1 25 | $490.0K | $1.4M | ||
| Q4 24 | $-283.0K | $4.7M | ||
| Q3 24 | $311.0K | $2.2M | ||
| Q2 24 | $-1.8M | $4.6M | ||
| Q1 24 | $-919.0K | $-8.0M |
自由现金流CSBRRENT
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
自由现金流率CSBRRENT
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
资本支出强度CSBRRENT
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
现金转化率CSBRRENT
| Q4 25 | -6.47× | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
RENT
暂无分部数据
